77
Participants
Start Date
July 8, 2022
Primary Completion Date
June 26, 2024
Study Completion Date
June 26, 2024
Magrolimab
Administered intravenous infusion
Bevacizumab
Administered intravenous infusion
Irinotecan
Administered intravenous infusion
Fluorouracil
Administered intravenous infusion
Leucovorin
Administered intravenous infusion
Hong Kong Integrated Oncology Centre, Hong Kong
Kinghorn Cancer Centre, Darlinghurst
Genesis Care North Shore, St Leonards
Westmead Hospital, Blacktown
Southside Cancer Care Centre, Miranda
The Alfred Hospital, Melbourne
Austin Health, Heidelberg
Princess Alexandra Hospital, Woolloongabba
Flinders Medical Centre, Bedford Park
Centre Hospitalizer De L'Ardenne, Libramont-Chevigny
Hôpital de Jolimont, Haine-Saint-Paul
Hospital Universitari Vall d'Hebron, Barcelona
Institut Català d'Oncologia- Hospital Duran I Reynals, L'Hospitalet de Llobregat
Hematology Oncology Associates of Central New York, PC, East Syracuse
Roswell Park Cancer Institute, Buffalo
AdventHealth, Rochester
Pennsylvania Hospital, Philadelphia
Fox Chase Cancer Center, Philadelphia
Virginia Cancer Specialists, PC, Arlington
Centre Hospitalier Regional Universitaire Hopital Besancon, Besançon
Hospital General Universitario Gregorio Marañón, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital HM Sanchinarro, Madrid
Orlando Health Cancer Institute, Orlando
Istituto Oncologico Veneto (IOV)- IRCCS, Padua
San Bortolo General Hospital- Oncology Department, Vicenza
CHU de Tours, Tours
Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne
"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - Medical Oncology Department", Meldola
University of Michigan, Ann Arbor
Azienda Ospedaliera Universitaria Pisana- UO Oncologia Medica, Pisa
Avera Cancer Institute, Sioux Falls
University of Kansas, Westwood
Centre Léon Bérard - Centre de Lutte contre le Cancer, Lyon
Istituto di Ricovero e Cura a Carattere Scientifico - Istituto Clinico Humanitas, San Giovanni Rotondo
Hopital franco brittanique, Paris
Texas Oncology, Dallas
Baylor College of Medicine Medical Center, Houston
Klinikum rechts der Isar der TU Munchen Zentrum fur klinische Studien der Klinik und Poliklinik fur Innere Medizin III, München
USC Norris Comprehensive Cancer Center, Los Angeles
University of California Los Angeles (UCLA), Santa Monica
Torrance Memorial Physician Network, Redondo Beach
City of Hope ( City of Hope National Medical Center, City of Hope Medical Center ), Duarte
Stanford Cancer Center, Palo Alto
Seattle Cancer Care Alliance (SCCA), Seattle
Sarah Cannon Research Institute, Nashville
The Ottawa Hospital Cancer Centre, Ottawa
Princess Margaret Cancer Centre, Toronto
Carl Gustav Carus Management GMBH, Dresden
Queen Mary Hospital, Hong Kong
Pan American Center for Oncology Trials, LLC, San Juan
Lead Sponsor
Gilead Sciences
INDUSTRY